Triple basepair changes within and adjacent to the conserved YY1 motif upstream of the U3 enhancer repeats of SL3-3 murine leukemia virus cause a small but significant shortening of latency of T-lymphoma induction

Virology

Volumn 313, Issue 2, 2003, Pages 638-644

  Ma, Shi Liang ^a   Lovmand, Jette ^a,c   Sørensen, Annette Balle ^a   Luz, Arne ^b   Schmidt, Jörg ^b   Pedersen, Finn Skou ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c Science Park   (Denmark)

Author keywords

Lymphomagenicity; Murine leukemia virus; SL3 3; Upstream conserved region; YY1

Indexed keywords

RETROVIRUS VECTOR; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASE PAIRING; IN VIVO STUDY; MODEL; MOUSE; MURINE LEUKEMIA VIRUS; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; T CELL LYMPHOMA; VIRUS CELL INTERACTION; VIRUS LATENCY; VIRUS MUTANT; VIRUS PATHOGENESIS; WILD TYPE;

MURINAE; MURINE LEUKEMIA VIRUS;

EID: 0042386626     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0042-6822(03)00379-9     Document Type: Article

References (36)

1. Amtoft H.W., Sorensen A.B., Bareil C., Schmidt J., Luz A., Pedersen F.S. Stability of AML1 (core) site enhancer mutations in T lymphomas induced by attenuated SL3-3 murine leukemia virus mutants. J. Virol. 71:(7):1997;5080-5087.
2. Ayuk F., Li Z., Kuhlcke K., Lindemann C., Schade U., Eckert H.G., Zander A., Fehse B. Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirements. Gene Ther. 6:(10):1999;1788-1792.
3. Baum C., Hegewisch-Becker S., Eckert H.G., Stocking C., Ostertag W. Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J. Virol. 69:(12):1995;7541-7547.
4. Baum C., Itoh K., Meyer J., Laker C., Ito Y., Ostertag W. The potent enhancer activity of the polycythemic strain of spleen focus-forming virus in hematopoietic cells is governed by a binding site for Sp1 in the upstream control region and by a unique enhancer core motif, creating an exclusive target for PEBP/CBF. J. Virol. 71:(9):1997;6323-6331.
5. Challita P.M., Skelton D., el-Khoueiry A., Yu X.J., Weinberg K., Kohn D.B. Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J. Virol. 69:(2):1995;748-755.
6. Chatis P.A., Holland C.A., Silver J.E., Frederickson T.N., Hopkins N., Hartley J.W. A 3′ end fragment encompassing the transcriptional enhancers of nondefective Friend virus confers erythroleukemogenicity on Moloney leukemia virus. J. Virol. 52:(1):1984;248-254.
7. DesGroseillers L., Jolicoeur P. The tandem direct repeats within the long terminal repeat of murine leukemia viruses are the primary determinant of their leukemogenic potential. J. Virol. 52:(3):1984;945-952.
8. DiFronzo N.L., Leung C.T., Mammel M.K., Georgopoulos K., Taylor B.J., Pham Q.N. Ikaros, a lymphoid-cell-specific transcription factor, contributes to the leukemogenic phenotype of a mink cell focus-inducing murine leukemia virus. J. Virol. 76:(1):2002;78-87.
9. Ethelberg S., Hallberg B., Lovmand J., Schmidt J., Luz A., Grundstrom T., Pedersen F.S. Second-site proviral enhancer alterations in lymphomas induced by enhancer mutants of SL3-3 murine leukemia virus negative effect of nuclear factor 1 binding site . J. Virol. 71:(2):1997;1196-1206.
10. Ethelberg S., Lovmand J., Schmidt J., Luz A., Pedersen F.S. Increased lymphomagenicity and restored disease specificity of AML1 site (core) mutant SL3-3 murine leukemia virus by a second-site enhancer variant evolved in vivo. J. Virol. 71:(10):1997;7273-7280.
11. Ethelberg S., Sorensen A.B., Schmidt J., Luz A., Pedersen F.S. An SL3-3 murine leukemia virus enhancer variant more pathogenic than the wild type obtained by assisted molecular evolution in vivo. J. Virol. 71:(12):1997;9796-9799.
12. Ethelberg S., Tzschaschel B.D., Luz A., Diaz-Cano S.J., Pedersen F.S., Schmidt J. Increased induction of osteopetrosis, but unaltered lymphomagenicity, by murine leukemia virus SL3-3 after mutation of a nuclear factor 1 site in the enhancer. J. Virol. 73:(12):1999;10406-10415.
13. Flanagan J.R., Becker K.G., Ennist D.L., Gleason S.L., Driggers P.H., Levi B.Z., Appella E., Ozato K. Cloning of a negative transcription factor that binds to the upstream conserved region of Moloney murine leukemia virus. Mol. Cell. Biol. 12:(1):1992;38-44.
14. Flanagan J.R., Krieg A.M., Max E.E., Khan A.S. Negative control region at the 5′ end of murine leukemia virus long terminal repeats. Mol. Cell. Biol. 9:(2):1989;739-746.
15. Golemis E.A., Speck N.A., Hopkins N. Alignment of U3 region sequences of mammalian type C viruses identification of highly conserved motifs and implications for enhancer design . J. Virol. 64:(2):1990;534-542.
16. Hallberg B., Schmidt J., Luz A., Pedersen F.S., Grundstrom T. SL3-3 enhancer factor 1 transcriptional activators are required for tumor formation by SL3-3 murine leukemia virus. J. Virol. 65:(8):1991;4177-4181.
17. Hanecak R., Pattengale P.K., Fan H. Deletion of a GC-rich region flanking the enhancer element within the long terminal repeat sequences alters the disease specificity of Moloney murine leukemia virus. J. Virol. 65:(10):1991;5357-5363.
18. Hyde-DeRuyscher R.P., Jennings E., Shenk T. DNA binding sites for the transcriptional activator/repressor YY1. Nucleic Acids Res. 23:(21):1995;4457-4465.
19. Ishimoto A., Takimoto M., Adachi A., Kakuyama M., Kato S., Kakimi K., Fukuoka K., Ogiu T., Matsuyama M. Sequences responsible for erythroid and lymphoid leukemia in the long terminal repeats of Friend-mink cell focus-forming and Moloney murine leukemia viruses. J. Virol. 61:(6):1987;1861-1866.
20. Laimins L.A., Gruss P., Pozzatti R., Khoury G. Characterization of enhancer elements in the long terminal repeat of Moloney murine sarcoma virus. J. Virol. 49:(1):1984;183-189.
21. Lenz J., Celander D., Crowther R.L., Patarca R., Perkins D.W., Haseltine W.A. Determination of the leukaemogenicity of a murine retrovirus by sequences within the long terminal repeat. Nature. 308:(5958):1984;467-470.
22. Li Y., Golemis E., Hartley J.W., Hopkins N. Disease specificity of nondefective Friend and Moloney murine leukemia viruses is controlled by a small number of nucleotides. J. Virol. 61:(3):1987;693-700.
23. Lovmand J., Sorensen A.B., Schmidt J., Ostergaard M., Luz A., Pedersen F.S. B-Cell lymphoma induction by akv murine leukemia viruses harboring one or both copies of the tandem repeat in the U3 enhancer. J. Virol. 72:(7):1998;5745-5756.
24. Morrison H.L., Soni B., Lenz J. Long terminal repeat enhancer core sequences in proviruses adjacent to c-myc in T-cell lymphomas induced by a murine retrovirus. J. Virol. 69:(1):1995;446-455.
25. Nieves A., Levy L.S., Lenz J. Importance of a c-Myb binding site for lymphomagenesis by the retrovirus SL3-3. J. Virol. 71:(2):1997;1213-1219.
26. Osborne C.S., Pasceri P., Singal R., Sukonnik T., Ginder G.D., Ellis J. Amelioration of retroviral vector silencing in locus control region beta-globin-transgenic mice and transduced F9 embryonic cells. J. Virol. 73:(7):1999;5490-5496.
27. Pattengale, P.K., 1994. Tumours of the lymphohaematopoietic system. IARC Sci. Publ.(111), 651-670.
28. Prasad Alur R.K., Foley B., Parente M.K., Tobin D.K., Heuer G.G., Avadhani A.N., Pongubala J., Wolfe J.H. Modification of multiple transcriptional regulatory elements in a Moloney murine leukemia virus gene transfer vector circumvents silencing in fibroblast grafts and increases levels of expression of the transferred enzyme. Gene Ther. 9:(17):2002;1146-1154.
29. Rao A., Luo C., Hogan P.G. Transcription factors of the NFAT family regulation and function . Annu. Rev. Immunol. 15:1997;707-747.
30. Schmidt J., Erfle V., Pedersen F.S., Rohmer H., Schetters H., Marquart K.H., Luz A. Oncogenic retrovirus from spontaneous murine osteomas. I. Isolation and biological characterization. J. Gen. Virol. 65:(12):1984;2237-2248.
31. Sorensen A.B., Duch M., Amtoft H.W., Jorgensen P., Pedersen F.S. Sequence tags of provirus integration sites in DNAs of tumors induced by the murine retrovirus SL3-3. J. Virol. 70:(6):1996;4063-4070.
32. Thomas M.J., Seto E. Unlocking the mechanisms of transcription factor YY1 are chromatin modifying enzymes the key? Gene. 236:(2):1999;197-208.
33. Tupper J.C., Chen H., Hays E.F., Bristol G.C., Yoshimura F.K. Contributions to transcriptional activity and to viral leukemogenicity made by sequences within and downstream of the MCF13 murine leukemia virus enhancer. J. Virol. 66:(12):1992;7080-7088.
34. Wahlers A., Kustikova O., Zipfel P., Itoh K., Koester M., Heberlein C., Li Z., Schiedlmeier B., Skerka C., Fehse B., Baum C. Upstream conserved sequences of mouse leukemia viruses are important for high transgene expression in lymphoid and hematopoietic cells. Mol. Ther. 6:(3):2002;313.
35. Wahlers A., Zipfel P.F., Schwieger M., Ostertag W., Baum C. In vivo analysis of retroviral enhancer mutations in hematopoietic cells SP1/EGR1 and ETS/GATA motifs contribute to long terminal repeat specificity . J. Virol. 76:(1):2002;303-312.
36. Yoshimura F.K., Diem K. Characterization of nuclear protein binding to a site in the long terminal repeat of a murine leukemia virus comparison with the NFAT complex . J. Virol. 69:(2):1995;994-1000.